<DOC>
	<DOCNO>NCT00005787</DOCNO>
	<brief_summary>RATIONALE : Peripheral stem cell transplantation may able replace immune cell destroy chemotherapy use kill cancer cell . Treating peripheral stem cell laboratory may improve effectiveness transplant . PURPOSE : Phase I trial study effectiveness peripheral stem cell transplantation patient relapse refractory non-Hodgkin 's lymphoma treat high-dose chemotherapy .</brief_summary>
	<brief_title>Peripheral Stem Cell Transplantation Prevent Neutropenia Patients Receiving Chemotherapy Relapsed Refractory Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine toxicity ex vivo expand peripheral blood mononuclear cell ( EVE PBMNC ) supplement high-dose chemotherapy conventional autograft patient relapse refractory non-Hodgkin 's lymphoma . - Compare effect EVE PBMNC white blood cell , red blood cell , platelet recovery patient study vs historical control , match protocol , disease status , prior therapy . - Determine optimal duration culture time harvest production neutrophil vivo . - Determine relationship length culture , immunophenotype , clinical outcome . - Determine required number white blood cell precursor clinical efficacy . - Assess need multiple transfusion EVE PBMNC post-transplantation period . OUTLINE : Autologous peripheral blood mononuclear cell ( PBMNC ) harvest . Unselected PBMNC culture expand ex vivo flt3 ligand , interleukin-3 , filgrastim ( G-CSF ) , sargramostim ( GM-CSF ) , epoetin alfa 13 day . Expanded PBMNC reinfused day 0 . Patients follow monthly 1 year . PROJECTED ACCRUAL : A total 24 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<mesh_term>Flt3 ligand protein</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven relapsed refractory nonHodgkin 's lymphoma Scheduled undergo highdose chemotherapy ( carmustine , etoposide , cytarabine , melphalan ) autologous peripheral blood mononuclear cell transplantation No metastatic disease involve bone marrow PATIENT CHARACTERISTICS : Age : 17 65 Performance status : ECOG 0 1 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count great 1,500/mm^3 Platelet count great 100,000/mm^3 Hepatic : No active hepatitis B C Bilirubin less 2.5 time normal* SGOT SGPT less 2.5 time normal* Alkaline phosphatase less 2.5 time normal NOTE : * Unless Gilbert 's syndrome present Renal : Creatinine clearance great 50 mL/min Cardiovascular : Cardiac ejection fraction normal Pulmonary : DLCO least 50 % predict FEV_1 FVC least 75 % predict Other : HIV negative Not pregnant Negative pregnancy test No nonneoplastic disease would preclude intensive chemotherapy PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics Chemotherapy : See Disease Characteristics Endocrine therapy : Not specify Radiotherapy : No prior external beam radiotherapy 25 % active bone marrow Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>neutropenia</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>